Ozempic, Wegovy, Mounjaro and Zepbound NAION Vision Loss Lawsuit Lawyers

FDA Requires New GLP-1 Drug Warnings About Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), a Rare Eye Condition That Can Cause Sudden, Permanent Vision Loss.

What Parker Waichman LLP Found

• New FDA warning: On November 9, 2026, the FDA required GLP-1 drug manufacturers to add warnings about the potential risk of NAION.
• Multiple medications affected: The requirement includes Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1 medications.
• Permanent vision loss: NAION can cause sudden, painless blindness or substantial visual impairment, typically affecting one eye.
• Safety concerns identified: The FDA reviewed adverse event reports and clinical trial information after research raised concerns about a possible association.
• Potential lawsuits: Patients diagnosed with NAION after GLP-1 treatment may be able to investigate failure-to-warn or other pharmaceutical liability claims, depending on the evidence and applicable law.

The U.S. Food and Drug Administration (FDA) announced on November 9, 2026, that manufacturers of GLP-1 medications must add safety warnings concerning a potentially increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a serious eye condition associated with sudden vision loss. The labeling requirement applies to GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, which are widely prescribed for Type 2 diabetes, weight management, and related medical conditions.

NAION develops when blood flow to part of the optic nerve becomes insufficient, damaging the nerve responsible for transmitting visual information to the brain. Patients may experience sudden, painless vision loss, often affecting one eye. The damage can be permanent, and there is currently no established treatment proven to reverse the resulting vision loss.

The FDA’s announcement raises important questions for patients who developed NAION while using GLP-1 medications, particularly those who were not previously informed about this potential complication. Although the agency identified a possible increased risk, it has not established that these medications caused every reported case. Patients who suffered serious visual impairment may nevertheless have grounds to investigate whether a pharmaceutical product liability lawsuit is appropriate.

Which GLP-1 Medications Are Included in the FDA’s New Blindness Warning?

The FDA’s labeling requirement applies to the GLP-1 receptor agonist drug class, not just one manufacturer or medication. Among the affected medications are Ozempic, Wegovy, and Rybelsus, which contain semaglutide, as well as Mounjaro and Zepbound, which contain tirzepatide. Other affected medications include Trulicity, Victoza, Saxenda, and additional GLP-1 treatments.

These medications work through hormone-related pathways that help regulate blood sugar and appetite. Some are prescribed for diabetes, while others are approved for weight management or additional medical conditions. Although these treatments can provide important health benefits, patients and prescribing physicians must have accurate information about potentially serious adverse reactions.

The FDA directed manufacturers to include NAION risk information in the Warnings and Precautions section of their prescribing labels. This requirement does not constitute a recall or establish that every patient taking these medications will experience vision problems.

What Is NAION, and How Can It Cause Permanent Blindness?

Nonarteritic anterior ischemic optic neuropathy is a condition involving reduced blood supply to the front portion of the optic nerve. When this occurs, nerve tissue may become damaged, interfering with the transmission of visual information from the eye to the brain.

Unlike some eye conditions that develop gradually, NAION can cause sudden vision loss without pain. Patients may discover the problem when they wake up, notice missing areas in their visual field, or experience unexpected difficulty reading and recognizing objects.

Symptoms may include blurred central vision, blind spots, tunnel vision, and changes in color perception. Although the condition frequently affects one eye initially, a person who experiences NAION may face an increased risk of developing the condition in the other eye.

There is no established treatment proven to reverse NAION-related vision loss. Any sudden change in vision requires immediate medical attention because other serious eye conditions can produce similar symptoms and may require urgent treatment.

What Did the FDA’s Investigation Reveal About GLP-1 Drugs and NAION?

The FDA began examining the potential association following research published in JAMA Ophthalmology in 2024 that raised concerns about NAION among patients prescribed semaglutide.

The agency subsequently reviewed adverse event reports, observational research, animal studies, and clinical trial data. Its analysis of 126 randomized controlled trials included more than 134,000 patients and identified 15 probable NAION events, including ten among GLP-1 users and five among comparator-treated patients.

The FDA calculated an incidence rate of 6.4 NAION events per 100,000 person-years among GLP-1 recipients, compared with 3.8 per 100,000 person-years among comparator recipients. A person-year represents one person followed for one year.

The agency’s real-world analyses produced mixed comparisons. One analysis found an increased risk compared with certain diabetes medications but not a statistically significant increase compared with another class. The FDA also acknowledged that diabetes, hypertension, obesity-related conditions, and sleep apnea can complicate assessments of causation.

Ultimately, the FDA concluded that a potential increased risk warranted additional warnings. It did not establish the biological mechanism or determine that GLP-1 treatment caused every reported NAION case.

How Permanent Vision Loss Can Affect Patients and Their Families

Sudden visual impairment can disrupt nearly every aspect of daily life. Individuals who previously drove, worked independently, and performed ordinary household activities may struggle with reading, computer use, transportation, and tasks requiring accurate depth perception.

Patients with significant vision loss may need additional medical evaluations, visual rehabilitation, adaptive technology, workplace accommodations, or assistance with everyday activities. Some may lose employment opportunities or experience reduced earning capacity.

Permanent impairment can also create emotional and financial consequences, particularly when patients fear additional damage to their remaining vision. The extent of these losses depends on the individual’s diagnosis, functional limitations, medical history, and employment circumstances.

For individuals who establish a legally actionable pharmaceutical injury claim, these consequences may be relevant when evaluating damages.

Can Patients File Ozempic, Wegovy, Mounjaro, or Zepbound Blindness Lawsuits?

Patients diagnosed with NAION after using a GLP-1 medication may have grounds to investigate a pharmaceutical product liability claim. Potential allegations could involve inadequate safety warnings, failure to communicate known risks, or other legally recognized product defects.

However, the FDA’s labeling decision does not automatically establish manufacturer liability. A lawsuit must address applicable legal requirements, including whether the manufacturer had a legally enforceable duty, whether that duty was breached, and whether the alleged failure caused the patient’s injury.

Prescription drug cases may also involve federal preemption questions, the timing of scientific evidence, and differences between state product liability laws. The date of treatment, the specific medication, existing warnings, and the patient’s medical history may materially affect the claim.

A detailed investigation is necessary to determine whether the evidence supports litigation.

What Compensation May Be Available in a GLP-1 Vision Loss Lawsuit?

When a patient establishes that a legally actionable failure caused permanent visual impairment, potential compensation may include past and future medical expenses, rehabilitation costs, lost wages, and reduced future earning capacity.

Depending on applicable state law, recoverable damages may also include pain and suffering, loss of enjoyment of life, and other consequences of permanent disability. Patients requiring assistance with daily activities may have additional future care expenses.

The amount of compensation depends on the severity of the injury, supporting medical evidence, applicable law, and proof of causation. No settlement or recovery is guaranteed.

GLP-1 Blindness and NAION Lawsuit FAQs

Can I sue Ozempic or Wegovy’s manufacturer if I developed NAION?

You may be able to investigate a product liability lawsuit if you developed NAION after taking Ozempic or Wegovy. A successful claim requires more than showing that the diagnosis occurred during treatment. Your medical records, prescribing history, the available scientific evidence, and applicable product liability law must support the claim. An attorney can evaluate whether the circumstances justify legal action.

Are Mounjaro and Zepbound included in the FDA’s NAION warning?

Yes. The FDA’s November 2026 requirement includes GLP-1 medications such as Mounjaro and Zepbound, which contain tirzepatide. The agency identified a potential increased risk across the medication class. However, the warning does not establish that tirzepatide caused an individual patient’s vision loss. Medical and legal evaluations remain necessary.

What symptoms should I watch for while taking a GLP-1 medication?

Warning signs include sudden painless vision loss, blind spots, tunnel vision, blurred central vision, or changes in color perception. These symptoms require immediate medical assessment because several serious conditions can cause abrupt visual changes. Patients should not wait for symptoms to improve before obtaining care.

Should I stop taking Ozempic, Wegovy, Mounjaro, or Zepbound?

Do not independently discontinue a prescribed medication solely because of the new warning. Discuss the benefits and risks with your prescribing physician. If you develop sudden vision changes, seek immediate medical attention. If NAION is diagnosed, your healthcare professional can determine whether continued treatment is appropriate.

What evidence is important in a GLP-1 blindness lawsuit?

Relevant evidence may include ophthalmology records, diagnostic testing, prescription histories, pharmacy records, medication packaging, and documentation of when symptoms began. Records of diabetes, blood pressure, sleep apnea, and other potential NAION risk factors may also be important. Employment and financial records can help establish the consequences of permanent vision loss.

Does the FDA warning prove that GLP-1 medications cause blindness?

No. The FDA concluded that available evidence supports a potential increased risk of NAION, but the precise mechanism remains uncertain. The agency’s findings justify additional safety labeling without establishing causation in every case. Individual claims require an assessment of the medical evidence and relevant legal standards.

What damages can I seek for permanent NAION-related vision loss?

Depending on the facts and governing law, damages may include medical bills, future treatment expenses, lost income, diminished earning capacity, and compensation for pain and suffering. Severe visual impairment may also require adaptive equipment and ongoing assistance. The recoverable amount depends on the proven injuries and liability.

How long do I have to file a GLP-1 vision loss lawsuit?

Deadlines vary by state and may depend on when the injury occurred or reasonably could have been discovered. Some claims involve additional procedural requirements. Because evidence and filing deadlines can become important quickly, patients should obtain legal advice promptly after receiving a NAION diagnosis.

Contact Parker Waichman LLP for a Free GLP-1 Blindness Lawsuit Consultation

Sudden vision loss can permanently affect your ability to work, drive, support your family, and live independently. Patients who develop NAION after taking Ozempic, Wegovy, Mounjaro, Zepbound, or another GLP-1 medication deserve to understand whether a preventable pharmaceutical safety failure contributed to their injuries.

Parker Waichman LLP is a national GLP-1 vision loss law firm representing individuals harmed by dangerous medications and other allegedly defective products. The firm can review your medical history, medication exposure, diagnosis, and potential legal claims.

If you or someone you love developed NAION or suffered permanent vision loss while taking a GLP-1 medication, contact Parker Waichman LLP for a free consultation.

Call 1-800-YOUR-LAWYER (1-800-968-7529) to discuss your potential GLP-1 vision loss lawsuit. Regardless of your location or where your injury occurred, our nationwide product injury law firm is ready to assist you.